Correction: ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer

被引：0
|
作者：
Seung Hee Choi [1 ]
Hye Jung Jang [2 ]
Joo Dong Park [2 ]
Ki Seo Ryu [1 ]
Eunchong Maeng [1 ]
Seohyun Cho [1 ]
Hail Park [1 ]
Hae-Yun Jung [3 ]
Kyung-Soon Park [1 ]
机构：
[1] CHA University,Department of Biomedical Science
[2] Sungkyunkwan University,Department of Integrative Biotechnology
[3] Korea Institute of Radiological and Medical Sciences,Division of Radiation Biomedical Research
来源：
Journal of Experimental & Clinical Cancer Research | / 44卷 / 1期
关键词：
D O I：
10.1186/s13046-025-03388-6
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer
    Pan, Jhih-Kai
    Lin, Cheng-Han
    Kuo, Yao-Lung
    Ger, Luo-Ping
    Cheng, Hui-Chuan
    Yao, Yun-Chin
    Hsiao, Michael
    Lu, Pei-Jung
    ONCOGENE, 2021, 40 (09) : 1737 - 1751
  • [42] MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer
    Jhih-Kai Pan
    Cheng-Han Lin
    Yao-Lung Kuo
    Luo-Ping Ger
    Hui-Chuan Cheng
    Yun-Chin Yao
    Michael Hsiao
    Pei-Jung Lu
    Oncogene, 2021, 40 : 1737 - 1751
  • [43] CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis
    Dongwei Dou
    Xiaoyang Ren
    Mingli Han
    Xiaodong Xu
    Xin Ge
    Yuanting Gu
    Xinxing Wang
    Song Zhao
    Cancer Cell International, 20
  • [44] CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis
    Dou, Dongwei
    Ren, Xiaoyang
    Han, Mingli
    Xu, Xiaodong
    Ge, Xin
    Gu, Yuanting
    Wang, Xinxing
    Zhao, Song
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [45] Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
    Lei Nie
    Yongkun Wei
    Fei Zhang
    Yi-Hsin Hsu
    Li-Chuan Chan
    Weiya Xia
    Baozhen Ke
    Cihui Zhu
    Rong Deng
    Jun Tang
    Jun Yao
    Yu-Yi Chu
    Xixi Zhao
    Ye Han
    Junwei Hou
    Longfei Huo
    How-Wen Ko
    Wan-Chi Lin
    Hirohito Yamaguchi
    Jung-Mao Hsu
    Yi Yang
    Dean N. Pan
    Jennifer L. Hsu
    Celina G. Kleer
    Nancy E. Davidson
    Gabriel N. Hortobagyi
    Mien-Chie Hung
    Nature Communications, 11
  • [46] IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor
    Kim, Hye-Youn
    Huyen Trang Ha Thi
    Hong, Suntaek
    CANCER LETTERS, 2018, 415 : 30 - 39
  • [47] Circ-FOXO3 inhibits triple-negative breast cancer growth and metastasis via regulating WHSC1-H3K36me2-Zeb2 axis
    Chen, Danyang
    Zeng, Shanshan
    Qiu, Huisi
    Yang, Mingqiang
    Lin, Xin
    Lv, Xinwu
    Li, Pan
    Weng, Shaojuan
    Kou, Siyue
    Luo, Kai
    Liu, Zongcai
    Yi, Yanmei
    Liu, Hao
    CELLULAR SIGNALLING, 2024, 117
  • [48] Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway
    Ganesan, Kumar
    Xu, Cong
    Wu, Jianming
    Du, Bing
    Liu, Qingqing
    Sui, Yue
    Song, Cailu
    Zhang, Jinhui
    Tang, Hailin
    Chen, Jianping
    SCIENCE CHINA-LIFE SCIENCES, 2024, 67 (09) : 1849 - 1866
  • [49] Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway
    Kumar Ganesan
    Cong Xu
    Jianming Wu
    Bing Du
    Qingqing Liu
    Yue Sui
    Cailu Song
    Jinhui Zhang
    Hailin Tang
    Jianping Chen
    ScienceChina(LifeSciences), 2024, 67 (09) : 1849 - 1866
  • [50] Discovery of aurovertin B as a potent metastasis inhibitor against triple-negative breast cancer: Elucidating the complex role of the ATF3-DUSP1 axis
    Shen, Jian-Jun
    Yang, Xi
    Yu, Meng
    Li, Qing-Cui
    Wang, Ru-Yu
    Yu, Wen-Yan
    Zhang, Jia-Li
    Chen, Yi-Li
    Zhu, Wen-Ting
    Li, Jia
    Zhan, Zha-Jun
    Wu, Rui
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (01):
12345